logo

ABEO

Abeona Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ABEO fundamentals

Abeona Therapeutics (ABEO) released its earnings on Nov 12, 2025: revenue was 5.25M (YoY 0.00%), missed estimates; EPS was -0.1 (YoY +84.13%), beat estimates.
Revenue / YoY
5.25M
0.00%
EPS / YoY
-0.1
+84.13%
Report date
Nov 12, 2025
ABEO Earnings Call Summary for Q3,2025
  • ZEVASKYN Launch Momentum: Despite Q4 2025 patient treatment delay, Abeona reports 30 identified candidates (double Q2 levels) and 12 ZPOFs finalized, signaling strong demand.
  • Assay Issue Resolved: Manufacturing delay caused by a false positive sterility assay was resolved in November, enabling resumed biopsy collections.
  • Broad Payer Coverage: All major commercial payers and all 51 state Medicaid programs now cover ZEVASKYN, with CMS J-code simplifying claims.
  • Financial Strength: $207.5 million cash position supports operations for over 2 years, with narrowed net loss to $5.2 million in Q3 2025.
EPS
Revenue

Revenue & Expenses

Key Indicators

Abeona Therapeutics (ABEO) key financial stats and ratios, covering profitability, financial health, and leverage.
Abeona Therapeutics (ABEO)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Abeona Therapeutics (ABEO)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Abeona Therapeutics (ABEO)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Abeona Therapeutics (ABEO) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Abeona Therapeutics (ABEO) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield